Medical Field secures additional $35M funding for Progressive Failure Analysis system development
In a significant stride for the field of electrophysiology, Field Medical, a California-based company, is developing a pioneering technology to treat ventricular tachycardia (VT), a condition that has so far proven challenging for existing treatments. The company's latest innovation, the FieldForce platform, is a pulsed field ablation (PFA) system designed specifically for VT.
Field Medical recently concluded a successful Series B funding round, raising an additional $35 million. This brings the total funds raised by the company to $75 million. These funds will be instrumental in launching the pivotal Veritas trial and further developing the FieldForce system. The company aims to bolster its clinical and regulatory capabilities, setting the stage for significant advancements in VT treatment.
The FieldForce system stands out in the rapidly evolving PFA market, which is currently dominated by major players like Medtronic, Boston Scientific, and Johnson & Johnson, who primarily focus on atrial fibrillation (AFib). Field Medical's focus on VT allows it to carve out a unique niche, potentially reducing competition with these established players.
Louis Cannon, a physician and the founder and senior managing director of BioStar Capital, has commended Field Medical for addressing a difficult and under-addressed challenge in cardiology with real innovation and urgency. Steven Mickelsen, the founder of Field Medical and an electrophysiologist who invented the Farapulse PFA system, emphasises that VT is among the most underpenetrated segments in electrophysiology.
Mickelsen established Field Medical in 2022 with the vision of developing a PFA approach for VT. The company's physician-led approach provides unique insights, ensuring that the technology is tailored to meet the specific needs of VT treatment. This focus on tackling a difficult and under-addressed challenge in cardiology sets Field Medical apart from other companies, which primarily focus on AFib treatment.
PFA technology offers a potentially safer way to ablate the cardiac tissue causing abnormal heart rhythms. Ventricular tachycardia is an irregular heart rhythm that can lead to sudden death. By addressing this critical gap in electrophysiology, Field Medical's PFA system for VT is poised to offer a specialized treatment option that differentiates itself by targeting a previously underserved condition.
The funding round was led by BioStar Capital and Cue Growth, reflecting the confidence investors have in Field Medical's innovative approach to VT treatment. With the successful completion of the Series B funding and the imminent start of the Veritas trial, Field Medical is well-positioned to expand treatment options for VT patients and make significant strides in the field of cardiology.
References: [1] "Field Medical raises $40M for PFA in ventricular tachycardia". TechCrunch. April 23, 2025. [2] "Steven Mickelsen, Farapulse founder, eyes next frontier in pulsed field ablation". Cardiology Today. March 4, 2025.
- Field Medical, a California-based medtech company, is developing the FieldForce platform, an AI-driven pulsed field ablation (PFA) system to treat ventricular tachycardia (VT), using innovative research in health-and-wellness.
- The company recently concluded a successful Series B funding round, raising an additional $35 million, bringing the total funds to $75 million for the development of the FieldForce system and the pivotal Veritas trial.
- In the M&A landscape, Field Medical's focus on VT sets it apart from major players like Medtronic, Boston Scientific, and Johnson & Johnson, who primarily focus on atrial fibrillation (AFib).
- Louis Cannon, a physician and the founder of BioStar Capital, has commended Field Medical for addressing a difficult and under-addressed challenge in cardiology with real innovation.
- The unique devices developed by Field Medical, under the leadership of electrophysiologist and founder Steven Mickelsen, offer a potentially safer way to ablate the cardiac tissue causing irregular heart rhythms, making significant advancements in VT treatment and patient analytics.
- With the successful completion of the Series B funding, the impending start of the Veritas trial, and the strategic partnerships with BioStar Capital and Cue Growth, Field Medical is poised to expand treatment options for VT patients, furthering innovation in the field of electrophysiology and cardiology news.
